Skip to main content

Metastatic IDE196-001

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

Kevin Kim
Kevin Kim
Principal investigator
View Profile

Email Us to Enroll

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?